NASDAQ:ACOR Acorda Therapeutics (ACOR) Stock Price, News & Analysis → My next big prediction isn’t a prediction (From Porter & Company) (Ad) Free ACOR Stock Alerts $13.50 +1.10 (+8.87%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$13.02▼$14.1050-Day Range$12.00▼$17.5052-Week Range$8.98▼$24.20Volume5,062 shsAverage Volume3,903 shsMarket Capitalization$16.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Acorda Therapeutics alerts: Email Address Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit About Acorda Therapeutics Stock (NASDAQ:ACOR)Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.Read More ACOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACOR Stock News HeadlinesMarch 19, 2024 | americanbankingnews.comStockNews.com Begins Coverage on Acorda Therapeutics (NASDAQ:ACOR)March 18, 2024 | americanbankingnews.comAcorda Therapeutics, Inc. (NASDAQ:ACOR) Short Interest UpdateMarch 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… March 11, 2024 | finance.yahoo.comKlick Health Launches First AI Social Media Comment Moderator for Life Sciences IndustryMarch 11, 2024 | americanbankingnews.comStockNews.com Initiates Coverage on Acorda Therapeutics (NASDAQ:ACOR)February 28, 2024 | stocknews.com3 Biotech Stocks to Watch in March for SuccessFebruary 23, 2024 | benzinga.comAcorda Therapeutics Stock (NASDAQ:ACOR), Short Interest ReportFebruary 22, 2024 | benzinga.comAcorda Therapeutics Stock (NASDAQ:ACOR) Dividends: History, Yield and DatesMarch 19, 2024 | Banyan Hill Publishing (Ad)AI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… February 20, 2024 | msn.comAcorda: No policy vs. TikTok use in PNPFebruary 6, 2024 | msn.comAcorda: PNP can’t interfere with people’s initiative for Charter changeFebruary 5, 2024 | msn.comTeodoro, Acorda nix Mindanao separation from PhilippinesJanuary 31, 2024 | msn.comPNP chief Acorda tells ranks: Ignore ‘political noise’January 29, 2024 | finance.yahoo.comDementia and Movement Disorder Treatment Market to Grow by USD 8.55 billion, Market Share, Trends, and Growth Analysis - TechnavioJanuary 11, 2024 | markets.businessinsider.comAcorda Therapeutics To Regain Worldwide Commercialization Rights To FAMPYRAJanuary 10, 2024 | stocknews.com3 Biotech Stocks to Keep an Eye on in 2024January 8, 2024 | msn.comAcorda files raps vs person spreading false info in viral vlogJanuary 8, 2024 | msn.comAcorda slams vlogger in 'disinformation' driveJanuary 8, 2024 | msn.comAcorda files cybercrime raps vs person spreading false info in a vlogJanuary 7, 2024 | msn.comAcorda eyes Pinoy apps vs cybercrimesJanuary 6, 2024 | morningstar.comAcorda Therapeutics Inc ACORJanuary 4, 2024 | finance.yahoo.comAshvattha Therapeutics Announces the Appointment of Mehdi Paborji as Senior Vice President of Technical OperationsDecember 18, 2023 | stocknews.comModerna (MRNA) and Acorda Therapeutics (ACOR): Buy, Hold, or Sell in 2024?December 18, 2023 | finance.yahoo.comAcorda Therapeutics, Inc.'s (NASDAQ:ACOR) Shares Bounce 53% But Its Business Still Trails The IndustryDecember 15, 2023 | stocknews.com3 Biotech Stocks Flashing Year-End 'Buy' Signals"November 24, 2023 | stocknews.com3 Safe Biotech Stocks to Buy This WeekNovember 14, 2023 | finance.yahoo.comAcorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Call TranscriptSee More Headlines Receive ACOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/19/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:ACOR CUSIP00484M10 CIK1008848 Webwww.acorda.com Phone(914) 347-4300Fax914-347-4560Employees111Year Founded1995Profitability EPS (Most Recent Fiscal Year)($17.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,920,000.00 Net Margins-14.35% Pretax Margin-16.72% Return on Equity-21.45% Return on Assets-4.25% Debt Debt-to-Equity Ratio3.07 Current Ratio1.59 Quick Ratio1.21 Sales & Book Value Annual Sales$118.57 million Price / Sales0.14 Cash FlowN/A Price / Cash FlowN/A Book Value$77.13 per share Price / Book0.18Miscellaneous Outstanding Shares1,240,000Free Float1,210,000Market Cap$16.74 million OptionableNo Data Beta1.41 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Ron Cohen M.D. (Age 68)Founder, CEO, President & Director Comp: $984.15kMr. Michael A. Gesser M.B.A. (Age 61)Chief Financial Officer Comp: $459.15kMr. Kerry M. Clem (Age 54)Chief Commercial Officer Comp: $592.23kMr. Robert Morales (Age 56)Interim Principal Accounting Officer, Principal Financial Officer, VP of Finance & Controller Ms. Felicia VonellaVice President of Investor RelationsMr. Neil S. Belloff Esq. (Age 64)General Counsel & Corporate Secretary Ms. Tierney SaccavinoExecutive Vice President of Corporate CommunicationsMs. Denise J. DucaExecutive Vice President of Human ResourcesMr. Andrew Mayer J.D.Senior Vice PresidentSofia AliSenior VP of Operations & Strategic PlanningMore ExecutivesKey CompetitorsSAB BiotherapeuticsNASDAQ:SABSCurisNASDAQ:CRISBrainstorm Cell TherapeuticsNASDAQ:BCLICoeptis TherapeuticsNASDAQ:COEPSenti BiosciencesNASDAQ:SNTIView All Competitors ACOR Stock Analysis - Frequently Asked Questions How have ACOR shares performed in 2024? Acorda Therapeutics' stock was trading at $15.09 at the beginning of the year. Since then, ACOR shares have decreased by 10.5% and is now trading at $13.50. View the best growth stocks for 2024 here. Are investors shorting Acorda Therapeutics? Acorda Therapeutics saw a increase in short interest in the month of February. As of February 29th, there was short interest totaling 11,100 shares, an increase of 7.8% from the February 14th total of 10,300 shares. Based on an average trading volume of 4,700 shares, the days-to-cover ratio is presently 2.4 days. Approximately 0.9% of the shares of the stock are short sold. View Acorda Therapeutics' Short Interest. When is Acorda Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ACOR earnings forecast. How were Acorda Therapeutics' earnings last quarter? Acorda Therapeutics, Inc. (NASDAQ:ACOR) issued its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($28.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($31.20) by $2.60. The biopharmaceutical company had revenue of $31.46 million for the quarter, compared to the consensus estimate of $30.57 million. Acorda Therapeutics had a negative trailing twelve-month return on equity of 21.45% and a negative net margin of 14.35%. When did Acorda Therapeutics' stock split? Acorda Therapeutics shares reverse split before market open on Monday, June 5th 2023. The 1-20 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Ron Cohen's approval rating as Acorda Therapeutics' CEO? 39 employees have rated Acorda Therapeutics Chief Executive Officer Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among the company's employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Acorda Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT). Who are Acorda Therapeutics' major shareholders? Acorda Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Acorda Therapeutics? Shares of ACOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACOR) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Companytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acorda Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.